Joining Forces to Understand Parkinson Disease
نویسندگان
چکیده
منابع مشابه
Joining Forces to Understand Parkinson Disease
The purpose of the study was to explore associations between neurocognitive function and chronic kidney disease (CKD)-related clinical characteristics. Twenty-nine children, ages 7 to 19 years, with an estimated creatinine clearance (eCrCl) of 4–89 ml/min per 1.73 m body surface area were enrolled. Intellectual function (IQ), memory, and attention were measured and expressed as age-based standa...
متن کاملJoining forces for children's health.
From airborne particulatesto pesticide-laden fruit, children probably encounter more pollutants than adults. Because their bodies are rapidly developing, children may react more strongly to these toxins, too. The NIEHS hopes to learn more about how several hazardous agents specifically affect kids. Together, the NIEHS and the EPA are spending $10 million to establish up to six Centers for Child...
متن کاملAn algorithmic approach to understand trace elemental homeostasis in serum samples of Parkinson disease
A classical problem in neurological disorders is to understand the progression of disorder and define the trace elements (metals) which play a role in deviating a sample from normal to an abnormal state, which implies the need to create a reference knowledge base (KB) employing the control samples drawn from normal/healthy set in the context of the said neurological disorder, and in sequel to a...
متن کاملUsing Medical Claims Analyses to Understand Interventions for Parkinson Patients
The scientific evidence to support the value of a range of non-pharmacological interventions for people with Parkinson's disease (PD) is increasing. However, showing unequivocally that specific interventions are better than usual care is not straightforward because of generic drawbacks of clinical trials. Here, we address these challenges, specifically related to the context of evaluating compl...
متن کاملRare Cancers Europe: joining forces to tackle a common problem
Rare cancers are not rare at all: they account for more than 20% of all cancers and affect more than 4 million people in the European Union. Every year, more than 500,000 people in the EU are diagnosed with a rare cancer.1 Evidence suggests that survival rates for rare cancers are lower than for common cancers2 and that cancer patients across Europe do not have equal access to cancer drugs.3,4 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Environmental Health Perspectives
سال: 2005
ISSN: 0091-6765,1552-9924
DOI: 10.1289/ehp.113-1253777